- Live Vaccines
- Attenuated Vaccines
Shingles Vaccine Market size was valued at USD 3.5 billion in 2022 and expected to reach USD 14.1 billion by 2029, at a significant CAGR of 13.8% from 2023-2029. Shingles is known as Herpes Zoster which causes a blistering painful rash on the skin which lasts from 2 to 4 weeks. But, for some people, the pain may last for months or years. This pain is called as (PHN) Post Herpetic Neuralgia, which is common complication of shingles and it occurrence increases with age. There are safe and effective vaccines are available for prevention of shingles. In 2006, Merck & Co., Inc. licenced Zostavax for prevention of shingles which is intended for people above 50years of age. In 2016, GSK received FDA approval for its Shingrix, vaccine to prevent shingles which has 90% efficiency in people than zostavax. GSK filed regulatory approvals in Europe, Canada and Japan for Shingrix. Shingles vaccine market is a very high consolidated market with very few market players. It is experiencing a rapid growth due to the new products and it may gain swift in market growth due to the new entrants into the market during the forecast period.
One key aspect contributing to the global market's overall growth is the increasing number of official recommendations to use these vaccinations. Furthermore, the growing number of senior individuals is predicted to fuel an ever-expanding industry. Many firms have spent a significant amount of money on research and development in order to create new shingles vaccines. This also contributes to a rise in the number of new product approvals by the FDA. The dangers linked with the vaccine's side effects, on the other hand, are extremely substantial. Furthermore, in the poor countries, there is a lack of understanding about supply and use of these products. In the years ahead, it is possible to pose a threat to the Shingles Vaccine Market's growth.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Increase in the prevalence and incidence of shingles disease around the world and increase in the global ageing population is expected to enhance the growth of shingles vaccine market across the globe. But, lack of awareness, high cost of the vaccination, unfavourable insurance coverage is major restraints of the global shingles vaccine market.
The Shingles vaccine market size was valued at USD 3.5 billion in 2022.
The key segments covered in the shingles vaccine market are technology, components, application, and end-users.
The Shingles vaccine market key players are Merck& Co., Inc. (U.S.), GlaxoSmithKline plc (UK), Cipla Inc. (India), Pfizer Inc. (U.S.)
1. Executive Summary |
2. Global Shingles Vaccine Market Introduction |
2.1. Global Shingles Vaccine Market Taxonomy |
2.2. Global Shingles Vaccine Market Definitions |
2.2.1. By Product Type |
2.2.2. By Vaccine Type |
2.2.3. By Region |
3. Global Shingles Vaccine Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Shingles Vaccine Market Dynamic Factors - Impact Analysis |
3.6. Impact of COVID-19 on The Market |
3.7. Three Forecast Scenarios - Pessimistic, Conservative, and Opportunistic |
3.8. Mapping Market Players Activities |
3.9. Recent Key Developments |
3.10. Financial Status of the Market Players |
3.11. Recent Acquisitions, Collaborations, and Mergers |
4. Global Shingles Vaccine Market Analysis, 2018-2022 and Forecast, 2023-2029 |
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Shingles Vaccine Market Forecast, By Product Type, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
5.1. Shingrix |
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Zostavax |
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. SKYZoster |
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Others |
5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6. Global Shingles Vaccine Market Forecast, By Vaccine Type, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
6.1. Recombinant Vaccine |
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Live Attenuated Vaccine |
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Global Shingles Vaccine Market Forecast, By Region, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia-Pacific |
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Latin America |
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Middle East and Africa |
7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
7.6. Global Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Distribution Channel, Vaccine Type, and Region, 2023-2029 |
8. North America Shingles Vaccine Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
8.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
8.1.1. Shingrix |
8.1.2. Sheath |
8.1.3. SKYZoster |
8.1.4. Others |
8.2. Vaccine Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
8.2.1. Recombinant Vaccine |
8.2.2. Live Attenuated Vaccine |
8.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
8.3.1. U.S. |
8.3.2. Canada |
8.4. North America Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2023-2029 |
8.5. North America Shingles Vaccine Market Dynamics Trends |
9. Europe Shingles Vaccine Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
9.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Shingrix |
9.1.2. Sheath |
9.1.3. SKYZoster |
9.1.4. Others |
9.2. Vaccine Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
9.2.1. Recombinant Vaccine |
9.2.2. Live Attenuated Vaccine |
9.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
9.3.1. Germany |
9.3.2. UK |
9.3.3. France |
9.3.4. Italy |
9.3.5. Spain |
9.3.6. Rest of Europe |
9.4. Europe Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2023-2029 |
9.5. Europe Shingles Vaccine Market Dynamics Trends |
10. Asia-Pacific Shingles Vaccine Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
10.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Shingrix |
10.1.2. Sheath |
10.1.3. SKYZoster |
10.1.4. Others |
10.2. Vaccine Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Recombinant Vaccine |
10.2.2. Live Attenuated Vaccine |
10.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
10.3.1. Japan |
10.3.2. China |
10.3.3. India |
10.3.4. ASEAN |
10.3.5. Rest of Asia-Pacific |
10.4. Asia-Pacific Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2023-2029 |
10.5. Asia-Pacific Shingles Vaccine Market Dynamics Trends |
11. Latin America Shingles Vaccine Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
11.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Shingrix |
11.1.2. Sheath |
11.1.3. SKYZoster |
11.1.4. Others |
11.2. Vaccine Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Recombinant Vaccine |
11.2.2. Live Attenuated Vaccine |
11.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Brazil |
11.3.2. Argentina |
11.3.3. Rest of Latin America |
11.4. Latin America Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2023-2029 |
11.5. Latin America Shingles Vaccine Market Dynamics Trends |
12. Middle East and Africa Shingles Vaccine Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
12.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Shingrix |
12.1.2. Sheath |
12.1.3. SKYZoster |
12.1.4. Others |
12.2. Vaccine Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Recombinant Vaccine |
12.2.2. Live Attenuated Vaccine |
12.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Saudi Arabia |
12.3.2. GCC Countries |
12.3.3. South Africa |
12.3.4. Rest of MEA |
12.4. MEA Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2023-2029 |
12.5. MEA Shingles Vaccine Market Dynamics Trends |
13. Competition Landscape |
13.1. Strategic Dashboard of Top Market Players |
13.2. Company Profiles (Introduction, Financial Analysis, Product Type Offerings, Key Developments, Strategies, and SWOT Analysis) |
13.2.1. GlaxoSmithKline plc. |
13.2.2. Merck & Co., Inc. |
13.2.3. SK chemicals |
13.2.4. Green Cross Corp |
13.2.5. CanSinoBIO |
13.2.6. Geneone Life Science |
13.2.7. Vaccitech |
13.2.8. Curevo Inc |
14. Research Methodology |
15. Key Assumptions and Acronyms |